Latest news with #AlexandriaRealEstateEquities
Yahoo
03-06-2025
- Business
- Yahoo
Is Alexandria Real Estate Positioned for a Rebound?
Alexandria Real Estate Equities, Inc. (ARE), an S&P 500 company, is a leading life science REIT that has pioneered the development of collaborative Megacampus ecosystems in premier innovation clusters such as Greater Boston, the San Francisco Bay Area, San Diego, and New York City since its founding in 1994. As of March 31, 2025, Alexandria boasts a market capitalization of $28.8 billion and an asset base comprising 39.6 million square feet of operating properties and 4 million square feet under construction. Alexandria Real Estate Equities' Megacampus properties are strategically located in premier U.S. life science innovation hubs, including Greater Boston's Kendall Square, the San Francisco Bay Area's Mission Bay and South San Francisco, San Diego's Sorrento Mesa and Torrey Pines, Seattle's Lake Union, Maryland's Rockville and Gaithersburg, New York City, and the Research Triangle Park in North Carolina. These campuses are situated near leading research institutions and universities, providing specialized facilities that attract and retain top-tier life science tenants as well highly educated and specialized employees. The company's Megacampus properties, which account for the majority of its revenue and operating space, have maintained high occupancy ratesaveraging 95% since 2021and attract a sector-leading client base of approximately 750 tenants, including many investment-grade and large-cap firms. Alexandria's business model emphasizes high-quality, long-term leases, resilient cash flows, and a strong balance sheet, with $5.3 billion in liquidity and a top-tier credit rating among U.S. REITs. The company continues to deliver incremental income through ongoing development and redevelopment, with most of its pipeline concentrated in its flagship Megacampus locations, reinforcing its position as the preeminent owner, operator, and developer in the life science real estate sector. While traditional office REITs have struggled with soaring vacancies due to the work-from-home trend, Alexandria Real Estate Equities (ARE) is largely immune from the work from home trend. Unlike typical office towers, Alexandria specializes in state-of-the-art biotech and pharmaceutical research labsspaces that simply can't be replicated easily. Alexandria has carved out a niche by developing research facilities on scarce land adjacent to top universities and bio-medical research hubs. This proximity is a major draw for biotech and pharma companies seeking to recruit and retain top talent. The company's 30-year track record as the S&P 500's flagship life sciences REIT speaks to its expertise and staying power. ARE boasts a diverse tenant base, including both major pharmaceutical firms and up-and-coming biotech companies. With 93% occupancy, long-term leases, high renewal rates, and predominantly triple-net leases with inflation protection, Alexandria enjoys stable, predictable cash flows. Since its 1997 IPO, ARE's total return (until recently) had outperformed the S&P 500. Investors currently enjoy a 7.47% dividend yield, with consistent annual increases5 year dividend growth rate is 5.4%. After Blackstone's $8B acquisition of Biomed Realty in 2016, Alexandria stands as the dominant player in the sector. With a market cap of $21.9B and significant development in the pipeline, it remains a potential acquisition target for larger institutional investors seeking reliable growth and income. Founder Joel Marcus, who started the company in 1994, remains executive chairman, ensuring continuity and mentorship for the current CEO. Heavy (86.1%) institutional ownership provides stability, reducing volatility from short-term retail traders. Among Guru Investors Jefferies and Renaissance are buying and Chris Davis (Trades, Portfolio) (Trades, Portfolio) is adding. Ron Baron (Trades, Portfolio) owns significant stock though he is reducing. The aging population in the Western world ensures ongoing demand for new medicines, and the pace of FDA approvals is accelerating. Biotech research isn't going anywhere, and Alexandria's assets are critical to the industry's progress. Alexandria's properties are highly specialized, with advanced lab infrastructure that meets stringent regulatory standards. Tenants often invest heavily in customizing their spaces, making them less likely to leave at lease endresulting in high retention. According to its most recent SEC filing for the fiscal year ended December 31, 2024, ARE reported an occupancy rate of 93.5% for its operating properties as of year-end 2024. The company continues to expand, including building research clusters leveraging its industry expertise to tap into global drug development. With a tenant roster that includes industry giants like Novartis, GSK, MIT, Bristol-Myers Squibb, Eli Lilly, and the U.S. Government, Alexandria is well-insulated from the financial troubles of any single firm. A mix of large and small tenants allows for organic growth within the portfolio. Alexandria's real estate is highly liquid, as evidenced by recent sales at premium prices per square foot. The company's land and construction quality ensure that, if needed, assets can be sold at attractive valuations. Alexandria Real Estate Equities maintains a conservative and well-staggered debt maturity profile, with only 13% of its total debt maturing through 2027. As of March 31, 2025, Alexandria's weighted-average remaining debt term is 12.2 yearsthe longest among S&P 500 REITsdemonstrating its focus on long-term financial stability. Approximately 30% of ARE's total debt matures in 2049 or later, reflecting a strategic emphasis on long-term financing. The company's balance sheet remains strong, with approximately $5.3 billion in liquidity and a high proportion of fixed-rate debt, helping to manage interest rate risk. Alexandria's net debt and preferred stock to adjusted EBITDA ratio stood at 5.9x for the first quarter of 2025, with a target to reduce it to 5.2x or lower by year-end. This prudent approach to debt management positions Alexandria as one of the most stable and resilient REITs in the sector. Alexandria is recycling capital by strategically selling non-core and stabilized assets, as well as partial interests in properties that do not fit its focus on large, high-demand mega campuses. The company uses proceeds from these sales to reinvest in its robust development and redevelopment pipeline, which centers on large-scale, highly leased research and development centers for leading life science companies. In 2024, for example, ARE sold five non-core properties in Greater Boston for $365 million and a fully leased property in San Diego for $86 million, both at attractive cap rates and strong value-creation margins. For the year, Alexandria targeted about $1.55 billion in capital from such dispositions and partial interest sales, with over $900 million already completed or under contract by mid-year. This disciplined approach to capital recycling allows ARE to fund new projects, reduce its reliance on issuing new equity, and take advantage of strong demand for high-quality life science real estate, supporting the company's long-term growth and value creation goals. FFO per share continues to climb but stock is down big time over the last 5 years. This discrepancy cannot continue for long and I expect the stock price to reverse in the next one to three years. FFO per share grew by 7.34% CAGR over the previous 5 years. Dividends per share grew by 5.08% CAGR over the same period. Funds from Operations (FFO) is a crucial financial metric for real estate investment trusts (REITs) that reflects the cash generated from their core operations. It is calculated by adding back non-cash expenses like depreciation and amortization to net income, while excluding gains from property sales and other one-time items. Unlike standard net income, FFO offers a more accurate view of a REIT's recurring profitability and its ability to pay dividends, since real estate assets typically appreciate over time even though accounting rules require depreciation. As a result, investors and analysts rely on FFO, often measured on a per-share basis, to assess the operating performance and financial health of REITs. ARE Data by GuruFocus ARE Data by GuruFocus Gurufocus Discounted Cash Flow (FCF based) calculator shows a robust margin of safety for Alexandria even with a 11% discount rate. Additionally the company's tangible book value per share is $102.86 again supporting the undervaluation thesis. The table below shows Alexandria's key valuation metrics as compared to selected large cap public US REIT's. Alexandria's valuation statistics compare favorably to its peers Symbol Current Price Company Market Cap ($M) Financial Strength Price-to-FFO PB Ratio PS Ratio Price-to-Free-Cash-Flow Price-to-Operating-Cash-Flow Equity-to-Asset Debt-to-Equity 3-Year Total Revenue Growth Rate Dividend Yield % ARE 70.19 Alexandria Real Estate Equities Inc 12142.09 4.00 7.64 0.68 3.97 8.80 8.80 0.46 0.77 13.10 7.47 BXP 67.33 BXP Inc 10660.00 3.00 12.01 2.00 3.10 8.53 8.53 0.21 3.09 5.70 5.82 VNO 37.67 Vornado Realty Trust 7230.73 3.00 12.00 1.75 4.08 13.25 13.25 0.34 1.60 4.00 1.96 CUZ 28.07 Cousins Properties Inc 4713.28 4.00 10.22 0.98 4.95 11.95 10.51 0.56 0.63 4.30 4.56 SLG 56.77 SL Green Realty Corp 4031.63 3.00 195.09 1.12 4.13 24.21 24.21 0.34 1.25 1.00 5.36 KRC 32.20 Kilroy Realty Corp 3808.64 4.00 6.94 0.71 3.38 112.98 7.47 0.49 0.88 5.90 6.71 Dividend payout is reasonable (below 60% of FFO) and shows large margin of safety. I do not expect a dividend cut. ARE Data by GuruFocus Part of Alexandria's stock price weakness can be explained by the increase of long term interest rates following the pandemic. This weakness has been aggravated by the current administrations sudden changes to trade tariffs causing bond prices to collapse. (Treasury bond prices go down as interest rates rise). I expect this sentiment to normalize in the short to medium term which should benefit Alexandria. Alexandria Real Estate Equities is a specialized, well-managed REIT with a proven business model, robust tenant demand, and strong growth prospects. Its focus on biotech and pharma research labswhere remote work isn't an optionand which sets it apart from traditional office REITs. With a rising dividend, high occupancy, sticky tenants and valuable real estate in prime locations, Alexandria is well positioned for a rebound. The company is also buying back stock (Buyback Yield 1.7%) which is unusual among REITs demonstration undervaluation. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
Is Alexandria Real Estate Positioned for a Rebound?
Alexandria Real Estate Equities, Inc. (ARE), an S&P 500 company, is a leading life science REIT that has pioneered the development of collaborative Megacampus ecosystems in premier innovation clusters such as Greater Boston, the San Francisco Bay Area, San Diego, and New York City since its founding in 1994. As of March 31, 2025, Alexandria boasts a market capitalization of $28.8 billion and an asset base comprising 39.6 million square feet of operating properties and 4 million square feet under construction. Alexandria Real Estate Equities' Megacampus properties are strategically located in premier U.S. life science innovation hubs, including Greater Boston's Kendall Square, the San Francisco Bay Area's Mission Bay and South San Francisco, San Diego's Sorrento Mesa and Torrey Pines, Seattle's Lake Union, Maryland's Rockville and Gaithersburg, New York City, and the Research Triangle Park in North Carolina. These campuses are situated near leading research institutions and universities, providing specialized facilities that attract and retain top-tier life science tenants as well highly educated and specialized employees. The company's Megacampus properties, which account for the majority of its revenue and operating space, have maintained high occupancy ratesaveraging 95% since 2021and attract a sector-leading client base of approximately 750 tenants, including many investment-grade and large-cap firms. Alexandria's business model emphasizes high-quality, long-term leases, resilient cash flows, and a strong balance sheet, with $5.3 billion in liquidity and a top-tier credit rating among U.S. REITs. The company continues to deliver incremental income through ongoing development and redevelopment, with most of its pipeline concentrated in its flagship Megacampus locations, reinforcing its position as the preeminent owner, operator, and developer in the life science real estate sector. While traditional office REITs have struggled with soaring vacancies due to the work-from-home trend, Alexandria Real Estate Equities (ARE) is largely immune from the work from home trend. Unlike typical office towers, Alexandria specializes in state-of-the-art biotech and pharmaceutical research labsspaces that simply can't be replicated easily. Alexandria has carved out a niche by developing research facilities on scarce land adjacent to top universities and bio-medical research hubs. This proximity is a major draw for biotech and pharma companies seeking to recruit and retain top talent. The company's 30-year track record as the S&P 500's flagship life sciences REIT speaks to its expertise and staying power. ARE boasts a diverse tenant base, including both major pharmaceutical firms and up-and-coming biotech companies. With 93% occupancy, long-term leases, high renewal rates, and predominantly triple-net leases with inflation protection, Alexandria enjoys stable, predictable cash flows. Since its 1997 IPO, ARE's total return (until recently) had outperformed the S&P 500. Investors currently enjoy a 7.47% dividend yield, with consistent annual increases5 year dividend growth rate is 5.4%. After Blackstone's $8B acquisition of Biomed Realty in 2016, Alexandria stands as the dominant player in the sector. With a market cap of $21.9B and significant development in the pipeline, it remains a potential acquisition target for larger institutional investors seeking reliable growth and income. Founder Joel Marcus, who started the company in 1994, remains executive chairman, ensuring continuity and mentorship for the current CEO. Heavy (86.1%) institutional ownership provides stability, reducing volatility from short-term retail traders. Among Guru Investors Jefferies and Renaissance are buying and Chris Davis (Trades, Portfolio) (Trades, Portfolio) is adding. Ron Baron (Trades, Portfolio) owns significant stock though he is reducing. The aging population in the Western world ensures ongoing demand for new medicines, and the pace of FDA approvals is accelerating. Biotech research isn't going anywhere, and Alexandria's assets are critical to the industry's progress. Alexandria's properties are highly specialized, with advanced lab infrastructure that meets stringent regulatory standards. Tenants often invest heavily in customizing their spaces, making them less likely to leave at lease endresulting in high retention. According to its most recent SEC filing for the fiscal year ended December 31, 2024, ARE reported an occupancy rate of 93.5% for its operating properties as of year-end 2024. The company continues to expand, including building research clusters leveraging its industry expertise to tap into global drug development. With a tenant roster that includes industry giants like Novartis, GSK, MIT, Bristol-Myers Squibb, Eli Lilly, and the U.S. Government, Alexandria is well-insulated from the financial troubles of any single firm. A mix of large and small tenants allows for organic growth within the portfolio. Alexandria's real estate is highly liquid, as evidenced by recent sales at premium prices per square foot. The company's land and construction quality ensure that, if needed, assets can be sold at attractive valuations. Alexandria Real Estate Equities maintains a conservative and well-staggered debt maturity profile, with only 13% of its total debt maturing through 2027. As of March 31, 2025, Alexandria's weighted-average remaining debt term is 12.2 yearsthe longest among S&P 500 REITsdemonstrating its focus on long-term financial stability. Approximately 30% of ARE's total debt matures in 2049 or later, reflecting a strategic emphasis on long-term financing. The company's balance sheet remains strong, with approximately $5.3 billion in liquidity and a high proportion of fixed-rate debt, helping to manage interest rate risk. Alexandria's net debt and preferred stock to adjusted EBITDA ratio stood at 5.9x for the first quarter of 2025, with a target to reduce it to 5.2x or lower by year-end. This prudent approach to debt management positions Alexandria as one of the most stable and resilient REITs in the sector. Alexandria is recycling capital by strategically selling non-core and stabilized assets, as well as partial interests in properties that do not fit its focus on large, high-demand mega campuses. The company uses proceeds from these sales to reinvest in its robust development and redevelopment pipeline, which centers on large-scale, highly leased research and development centers for leading life science companies. In 2024, for example, ARE sold five non-core properties in Greater Boston for $365 million and a fully leased property in San Diego for $86 million, both at attractive cap rates and strong value-creation margins. For the year, Alexandria targeted about $1.55 billion in capital from such dispositions and partial interest sales, with over $900 million already completed or under contract by mid-year. This disciplined approach to capital recycling allows ARE to fund new projects, reduce its reliance on issuing new equity, and take advantage of strong demand for high-quality life science real estate, supporting the company's long-term growth and value creation goals. FFO per share continues to climb but stock is down big time over the last 5 years. This discrepancy cannot continue for long and I expect the stock price to reverse in the next one to three years. FFO per share grew by 7.34% CAGR over the previous 5 years. Dividends per share grew by 5.08% CAGR over the same period. Funds from Operations (FFO) is a crucial financial metric for real estate investment trusts (REITs) that reflects the cash generated from their core operations. It is calculated by adding back non-cash expenses like depreciation and amortization to net income, while excluding gains from property sales and other one-time items. Unlike standard net income, FFO offers a more accurate view of a REIT's recurring profitability and its ability to pay dividends, since real estate assets typically appreciate over time even though accounting rules require depreciation. As a result, investors and analysts rely on FFO, often measured on a per-share basis, to assess the operating performance and financial health of REITs. ARE Data by GuruFocus ARE Data by GuruFocus Gurufocus Discounted Cash Flow (FCF based) calculator shows a robust margin of safety for Alexandria even with a 11% discount rate. Additionally the company's tangible book value per share is $102.86 again supporting the undervaluation thesis. The table below shows Alexandria's key valuation metrics as compared to selected large cap public US REIT's. Alexandria's valuation statistics compare favorably to its peers Symbol Current Price Company Market Cap ($M) Financial Strength Price-to-FFO PB Ratio PS Ratio Price-to-Free-Cash-Flow Price-to-Operating-Cash-Flow Equity-to-Asset Debt-to-Equity 3-Year Total Revenue Growth Rate Dividend Yield % ARE 70.19 Alexandria Real Estate Equities Inc 12142.09 4.00 7.64 0.68 3.97 8.80 8.80 0.46 0.77 13.10 7.47 BXP 67.33 BXP Inc 10660.00 3.00 12.01 2.00 3.10 8.53 8.53 0.21 3.09 5.70 5.82 VNO 37.67 Vornado Realty Trust 7230.73 3.00 12.00 1.75 4.08 13.25 13.25 0.34 1.60 4.00 1.96 CUZ 28.07 Cousins Properties Inc 4713.28 4.00 10.22 0.98 4.95 11.95 10.51 0.56 0.63 4.30 4.56 SLG 56.77 SL Green Realty Corp 4031.63 3.00 195.09 1.12 4.13 24.21 24.21 0.34 1.25 1.00 5.36 KRC 32.20 Kilroy Realty Corp 3808.64 4.00 6.94 0.71 3.38 112.98 7.47 0.49 0.88 5.90 6.71 Dividend payout is reasonable (below 60% of FFO) and shows large margin of safety. I do not expect a dividend cut. ARE Data by GuruFocus Part of Alexandria's stock price weakness can be explained by the increase of long term interest rates following the pandemic. This weakness has been aggravated by the current administrations sudden changes to trade tariffs causing bond prices to collapse. (Treasury bond prices go down as interest rates rise). I expect this sentiment to normalize in the short to medium term which should benefit Alexandria. Alexandria Real Estate Equities is a specialized, well-managed REIT with a proven business model, robust tenant demand, and strong growth prospects. Its focus on biotech and pharma research labswhere remote work isn't an optionand which sets it apart from traditional office REITs. With a rising dividend, high occupancy, sticky tenants and valuable real estate in prime locations, Alexandria is well positioned for a rebound. The company is also buying back stock (Buyback Yield 1.7%) which is unusual among REITs demonstration undervaluation. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Alexandria Real Estate Equities, Inc. to Hold Its Second Quarter 2025 Operating and Financial Results Conference Call and Webcast on July 22, 2025
PASADENA, Calif., May 29, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that the company will conduct a conference call and audio webcast on Tuesday, July 22, 2025 at 2:00 p.m. Eastern Time (ET), in conjunction with the release of its second quarter 2025 operating and financial results. Alexandria will release its operating and financial results after the market closes on Monday, July 21, 2025. To participate in this conference call, dial (833) 366-1125 (U.S.) or (412) 902-6738 shortly before 2:00 p.m. ET and ask the operator to join the call for Alexandria Real Estate Equities, Inc. The live audio webcast can be accessed on the company's website at A replay of the call will be available from 4:00 p.m. ET on Tuesday, July 22, 2025 through 4:00 p.m. ET on Tuesday, July 29, 2025. To access the replay, dial (877) 344-7529 (U.S.) or (412) 317-0088 and enter access code 1006663. About Alexandria Real Estate Equities, Inc. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@ View original content to download multimedia: SOURCE Alexandria Real Estate Equities, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Alexandria Real Estate Equities, Inc. Enhances Its Corporate Responsibility Pillar Focused on Driving Educational Opportunities With Opening of New Learning Lab at Fred Hutch Dedicated to Inspiring and Training Future Scientists
PASADENA, Calif., May 28, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today celebrates the opening of the Alexandria Real Estate Equities, Inc. Learning Lab at the Fred Hutch Cancer Center, an innovative laboratory environment to inspire and train the next generation of scientists and advance Fred Hutch's rich legacy of research and development in cancer and other diseases. The new state-of-the-art learning laboratory — designed and built out by Alexandria in close collaboration with Fred Hutch's Science Education and Facilities teams — will engage high school and college students, as well as school and community groups, in scientific education and training programs run by Fred Hutch. "We are deeply grateful for Alexandria's generosity and commitment to Fred Hutch and its vital role in constructing the new Alexandria Real Estate Equities, Inc. Learning Lab," said Thomas J. Lynch Jr., MD, president and director of Fred Hutch and holder of the Raisbeck Endowed Chair. "Alexandria's support of this space will have a profound impact on our ability to advance science education and reflects our shared belief that the best way to inspire future scientists is to provide incredible mentorship and training programs in a vibrant space that brings learning to life." The new Learning Lab provides Fred Hutch with a permanent, purpose-built space to host its scientific training programs, including those that involve hands-on experiments built around real-world scenarios in cancer diagnosis and treatment. Students will gain basic laboratory skills, such as pipetting and gel electrophoresis, while also learning about science education and careers. Over 225 high school and undergraduate students take part in scientific training programs at Fred Hutch's South Lake Union campus every year. To enrich the learning experience of future participants in Fred Hutch's science education and community partnership programs, the laboratory features modular benching, retractable screens, integrated audiovisual systems, an open central space to gather for discussions and an interior picture window that will showcase the students at work. This new environment, which is uniquely embedded within a Fred Hutch research facility, will expand the reach of the non-profit's education programs and transform its engagement with Seattle's students and community groups. "Since 1996, Alexandria has been at the forefront of cultivating a world-class life science innovation cluster in Seattle through our acquisition and leaseback of the original Fred Hutch campus — which marked the beginning of our relationship with Fred Hutch — and our first-ever strategic venture investment in Corixa Corporation (which was acquired by GlaxoSmithKline in 2005)," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "By bringing together leading-edge innovation across a diverse mix of life science and technology companies, top academic and medical institutions, skilled talent and investment capital, Alexandria — with the help of collaborative organizations like Fred Hutch — has led Seattle's growth into the thriving life science ecosystem it is today. The new Alexandria Learning Lab at Fred Hutch will further bolster our ecosystem-building efforts by training and mentoring future scientific innovators in this globally recognized region." "Fred Hutch is an important innovation engine and steward in the Seattle life science cluster, and we are honored to further strengthen our trusted relationship through our collaboration on the Alexandria Learning Lab," said Hart Cole, executive vice president of capital markets and strategic operations and co-regional market director for Seattle at Alexandria Real Estate Equities, Inc. "Our leadership in the Learning Lab at Fred Hutch demonstrates our deep commitment to supporting STEM education, cultivating the next generation of innovators and shaping the future of life science in Seattle and of human health around the world." The Alexandria Learning Lab at Fred Hutch is an important new initiative within the company's corporate responsibility pillar of building principled leaders through education. It highlights Alexandria's highly impactful action-oriented efforts to drive educational opportunities for students and provide needed resources to develop their talents and achieve academic and career success. About Alexandria Real Estate Equities, Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of March 31, 2025, Alexandria has a total market capitalization of $28.8 billion and an asset base in North America that includes 39.6 million RSF of operating properties and 4.0 million RSF of Class A/A+ properties undergoing construction. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impact of the Alexandria Learning Lab and Alexandria's partnership with the Fred Hutch Cancer Center; future opportunities for participants in Fred Hutch's community programs and student collaborations; and the likelihood of continued commitment to and sponsorship of programs relating to scientific training programs and initiatives. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@ View original content to download multimedia: SOURCE Alexandria Real Estate Equities, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-05-2025
- Business
- Globe and Mail
5 Top Dividend Stocks Yielding Over 5% to Buy for Passive Income
Investing in dividend stocks can be a great way to collect dividend income. Several high-quality companies currently offer higher-yielding dividends. That enables you to generate more passive income from every dollar you invest. Here are five top dividend stocks currently yielding over 5%, well above the S&P 500 's sub-1.5% dividend yield. At that rate, every $100 you invest will produce over $5 of passive dividend income each year. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Alexandria Real Estate Equities Alexandria Real Estate Equities (NYSE: ARE) is a real estate investment trust (REIT) focused on owning life science properties. It owns, operates, and develops collaborative megacampuses in life science innovation clusters, including Greater Boston, the San Francisco Bay area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. It leases space in its purpose-built lab and office buildings to biopharmaceutical companies, medical technology companies, and biomedical institutions. It uses a portion of the rent collected from these companies, accounting for 57% of its funds from operations, to pay a lucrative dividend that currently yields over 7%. It retains the rest to invest in developing, redeveloping, and acquiring additional lab properties. These investments have enabled Alexandria to grow its dividend at a 4.5% annual rate since the end of 2020. Clearway Energy Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A) is a leading owner of clean energy generation assets, including wind, solar, battery storage, and natural gas. The company sells the electricity that those assets produce under long-term, fixed-rate power purchase agreements with utilities and large corporate power buyers. Clearway targets to pay out 70% to 80% of its stable cash flow in dividends. It currently has a dividend yield of nearly 6%. The company uses the cash it retains and its solid balance sheet to invest in additional income-generating clean energy assets. It has investments lined up to grow its cash available for distribution from $2.08 per share this year to over $2.60 per share by 2027. That should give Clearway plenty of power to continue increasing its high-yielding dividend. Enbridge Enbridge (NYSE: ENB) is a leading North American pipeline and utility company. Those businesses generate very stable cash flow. The company pays out 60% to 70% of its steady cash flow in dividends, with a 6% current yield. The energy infrastructure company's post-dividend free cash flow and strong balance sheet give it billions of dollars in annual investment capacity. It uses that financial flexibility to invest in organic expansion projects and make accretive bolt-on acquisitions. Enbridge currently has expansion projects under construction that will come online through the end of the decade. That gives it a lot of visibility into its ability to continue growing its earnings and dividend, with plans for 3% to 5% annual growth in the coming years. Enbridge has grown its dividend for 30 consecutive years. NNN REIT NNN REIT (NYSE: NNN) is a REIT focused on owning income-generating freestanding net lease retail properties, such as convenience stores, auto service locations, and restaurants. Net leases produce very stable rental income because tenants cover all of a property's operating expenses, including routine maintenance, real estate taxes, and building insurance. NNN REIT uses that steady rental income to pay its dividend, which currently yields around 5.5%. The REIT expects to generate enough cash to pay its dividend with about $200 million to spare this year. It also has a conservative balance sheet. Those features give it the financial flexibility to buy additional income-generating retail properties. NNN REIT's steadily growing portfolio has enabled it to routinely increase its dividend. Last year was the 35th straight year that it had raised its payment. Verizon Verizon (NYSE: VZ) is one of the country's largest mobile and broadband companies. It generates lots of recurring revenue as customers pay their cellphone and internet bills. Last year, Verizon generated $19.8 billion in free cash flow after funding $17.1 billion in capital expenditures to maintain and expand its mobile and broadband networks. That easily covered its $11.2 billion dividend outlay, enabling the company to retain cash to strengthen its already rock-solid balance sheet. That puts the telecom giant's 6%-plus-yielding dividend payment on a rock-solid foundation. The company invests heavily in growing its business. It plans to continue spending billions of dollars on capital expenditures each year. Verizon also agreed to buy Frontier Communications in a $20 billion deal to enhance its fiber capabilities. These growth-focused investments should enable Verizon to continue increasing its high-yielding dividend, which it has raised for a sector-leading 18 straight years. Lots of passive income now and even more in the future These dividend stocks all share a few common features. They generate lots of stable cash flow, which they use to pay high-yielding dividends while investing in growing their businesses. That growth enables them to routinely raise their dividend payments. Investors, in turn, get to collect a lucrative passive income stream that should steadily grow in the future. Should you invest $1,000 in Enbridge right now? Before you buy stock in Enbridge, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Enbridge wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $642,582!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $829,879!* Now, it's worth noting Stock Advisor 's total average return is975% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
